New data reinforce positive clinical outcomes for direct aortic implants with the CoreValve system

New data presented at the PCR London Valves 2012 meeting has shown a 97% procedural success implantation with the CoreValve System (Medtronic) through a direct aortic approach. One hundred and fifty one patients from 15 centres across Europe and Israel were included in the study. There were no procedural deaths, the overall 30-day mortality rate was 8.6%, and the incidence of stroke was 3.9%.

Biosensors International Extends Licensing Agreement With Terumo Corporation to Sell BioMatrix Technology Globally

Biosensors and Terumo have agreed to extend the original licensing agreement for territories outside of Japan until December 2014, under terms similar to the original October 2003 agreement. Terumo also continues to benefit from its existing rights in Japan to manufacture, market and sell DES systems incorporating BioMatrix® technology.

Biosensors International Extends Licensing Agreement With Terumo Corporation to Sell BioMatrix Technology Globally

New Data Reinforce Positive Clinical Outcomes for Direct Aortic Implants Using the Medtronic, Inc. (MDT) Corevalve System

MINNEAPOLIS – October 2, 2012 – Medtronic, Inc. (NYSE: MDT) today reported two clinical research updates related to the Medtronic CoreValve® System direct aortic implantation approach, which received CE (Conformité Européenne) Mark in November 2011 for patients with severe aortic stenosis.

Biosensors International Extends Licensing Agreement With Terumo Corporation to Sell BioMatrix Technology Globally

SINGAPORE, Oct. 1, 2012 /PRNewswire-FirstCall/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20) and Terumo Corporation ("Terumo") announced today an extension of their existing licensing agreements, under which Terumo may continue to incorporate BioMatrix technology in the production, marketing and selling of Terumo s drug-eluting stent (DES) systems in markets worldwide, outside of the United States. Terumo is one of the world s leading medical device manufacturers.

Cardiac Dimensions initiates European distribution of Carillon Mitral Contour System

Cardiac Dimensions announced that it has initiated European commercialisation of its Carillon Mitral Contour System used in the treatment of patients suffering from functional mitral regurgitation (FMR).

FDA clears Emerge Balloon Dilatation Catheter

The US Food and Drug Administration (FDA) has given clearance to Boston Scientific for its Emerge Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Dilatation Catheter. The company has begun marketing the device in the United States.

CoreValve Evolut 23mm transcatheter aortic valve gets the CE mark

Medtronic has announced that it has received the CE mark for its CoreValve Evolut 23mm valve, its latest self-expanding transcatheter aortic valve implantation (TAVI) system.

Stentys launches enhanced stent-delivery system for Self-Apposing Stent

Stentys has released in Europe an enhanced stent-delivery system for its Self-Apposing Stent used in the treatment of acute myocardial infarction (AMI).

Absorb Bioresorbable Vascular Scaffold launched in Europe, parts of Asia Pacific and Latin America

On 25 September, Abbott announced that Absorb, the world’s first drug-eluting bioresorbable vascular scaffold (BVS), is now widely available across Europe and parts of Asia Pacific and Latin America.

Coronary artery stenting combined with minimally invasive valve surgery may be an alternative to CABG and valve surgery

A study lead by researchers from the Mount Sinai Medical Center in Miami, USA, has found that patients with coronary valvular disease who were treated with a hybrid approach combining coronary artery stenting with minimally invasive valve surgery showed significantly better outcomes than patients who had standard sternotomy coronary bypass and valve surgery.

Tiara valve for mitral regurgitation shows positive results in acute preclinical data

Acute results from preclinical studies of the Tiara valve (Neovasc) for the transcatheter treatment of mitral regurgitation have shown that implantation of Tiara valves was feasible, relatively straightforward and resulted in a securely-implanted, well-functioning device that maintained good haemodynamics in the test animals.

Alrededor de un millón de personas en España siguen una terapia anticoagulante oral en la actualidad

Madrid, septiembre de 2012.- En España hay actualmente un millón de personas que siguen una terapia anticoagulante oral; de ellas, cerca de 700.000 reciben tratamiento crónico y el resto uno temporal, en función de la necesidad que presenten de mantener los niveles de coagulación adecuados y de la causa de su problema.

Primus Drug-Coated Balloon shows efficacy in patients with in-stent restenosis of drug-eluting stents

Cardionovum has announced positive initial results of a preclinical study and a first-in-man clinical study of its Primus Drug-Coated Balloon (DCB).

Boston Scientific to acquire BridgePoint Medical

Boston Scientific has signed a definitive agreement to acquire BridgePoint Medical, developer of a proprietary, catheter-based system to treat coronary chronic total occlusions (CTOs).